These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10414411)

  • 1. Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease.
    Maesen BL; Westermann CJ; Duurkens VA; van den Bosch JM
    Eur Respir J; 1999 May; 13(5):1103-8. PubMed ID: 10414411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
    Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
    Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
    Richter K; Janicki S; Jörres RA; Magnussen H
    Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
    Celik G; Kayacan O; Beder S; Durmaz G
    Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
    Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
    Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
    van der Woude HJ; Winter TH; Aalbers R
    Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute relief of exercise-induced bronchoconstriction by inhaled formoterol in children with persistent asthma.
    Hermansen MN; Nielsen KG; Buchvald F; Jespersen JJ; Bengtsson T; Bisgaard H
    Chest; 2006 May; 129(5):1203-9. PubMed ID: 16685010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD.
    Cazzola M; Matera MG; Di Perna E; Califano C; D'Amato M; Mazzarella G
    Respir Med; 1999 Dec; 93(12):909-11. PubMed ID: 10653054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial.
    Aalbers R; Ayres J; Backer V; Decramer M; Lier PA; Magyar P; Malolepszy J; Ruffin R; Sybrecht GW
    Eur Respir J; 2002 May; 19(5):936-43. PubMed ID: 12030736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler.
    Ringdal N; Derom E; Wåhlin-Boll E; Pauwels R
    Respir Med; 1998 Aug; 92(8):1017-21. PubMed ID: 9893769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients.
    Tötterman KJ; Huhti L; Sutinen E; Backman R; Pietinalho A; Falck M; Larsson P; Selroos O
    Eur Respir J; 1998 Sep; 12(3):573-9. PubMed ID: 9762782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
    Szafranski W; Cukier A; Ramirez A; Menga G; Sansores R; Nahabedian S; Peterson S; Olsson H
    Eur Respir J; 2003 Jan; 21(1):74-81. PubMed ID: 12570112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
    Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
    Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine.
    Ketchell RI; Jensen MW; Spina D; O'Connor BJ
    Eur Respir J; 2002 Apr; 19(4):611-6. PubMed ID: 11998988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes.
    Carlsen KH; Hem E; Stensrud T; Held T; Herland K; Mowinckel P
    Respir Med; 2001 Jul; 95(7):571-6. PubMed ID: 11453313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
    Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
    Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airway disease. A 3-month, placebo-controlled comparison of the efficacy and safety of formoterol and salbutamol, followed by a 12-month trial with formoterol.
    Steffensen I; Faurschou P; Riska H; Rostrup J; Wegener T
    Allergy; 1995 Aug; 50(8):657-63. PubMed ID: 7503401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 3-month comparison of formoterol with terbutaline via turbuhaler. A placebo-controlled study.
    Ekström T; Ringdal N; Tukiainen P; Runnerström E; Soliman S
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):225-30. PubMed ID: 9759798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease.
    Stålenheim G; Wegener T; Grettve L; Lundbäck B; Melander B; Osterman K; Piitulainen E; Zetterström O
    Respiration; 1994; 61(6):305-9. PubMed ID: 7824809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.